Provided by Tiger Trade Technology Pte. Ltd.

Roundhill GLP-1 & Weight Loss ETF

29.93
-0.2559-0.85%
Post-market: 29.950.0121+0.04%19:30 EDT
Volume:9K
Turnover:279.68K
Market Cap:55.97M
PE:- -
High:30.22
Open:30.22
Low:29.84
Close:30.19
52wk High:37.15
52wk Low:27.34
Shares:1.87M
Float Shares:1.87M
Volume Ratio:0.84
T/O Rate:0.50%
Dividend:0.41
Dividend Rate:1.37%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

Kailera Therapeutics announces positive results from several presentations

TIPRANKS
·
Oct 01

Kailera Reports Phase 1 Data Showing Ribupatide Injection Exposure Similar Across Abdomen, Arm, Thigh Sites

Reuters
·
Oct 01

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

GlobeNewswire
·
Oct 01

Pfizer says Phase 2 study of tilrekimig met primary endpoint

TIPRANKS
·
Oct 01

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Oct 01

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Oct 01

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Oct 01

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - 62.5% of Patients on Tilrekimig 450 Mg Q2w Achieve Easi-75 vs 19.9% Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - Phase 2 Study Meets Primary Endpoint with Significant Easi-75 Improvement at Week 16

THOMSON REUTERS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

NYSE Most Active Issues

Dow Jones
·
Oct 01